DOCSLIB.ORG

Immediate Action New Tests and Test Updates

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Effective Date: Monday, August 26, 2013 New Tests and Test Updates Immediate Action In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, August 26, 2013 New Tests - Tests recently added to the NMS Labs test menu. New Tests are effective immediately. Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements. Discontinued Tests - Tests being discontinued with alternate testing suggestions. Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases. If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes. The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document. NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 1 of 76 Effective Date: Monday, August 26, 2013 New Tests and Test Updates Test Test Name New Test Method / Specimen Stability Scope Units Reference Discontinue Code Test Name CPT Code Req. Comments 7-Hydroxymitragynine, Mitragynine, Phenazepam 52381SP • Confirmation (Qualitative), Serum/Plasma Amphetamines Confirmation, 52370B • Blood Amphetamines Confirmation, 52409B • Blood (Forensic) Amphetamines Confirmation, 52370SP • Serum/Plasma Amphetamines Confirmation, 52409SP • Serum/Plasma (Forensic) Amphetamines Confirmation, 52370U • Urine Amphetamines Confirmation, 52409U • Urine (Forensic) Amphetamines 5223U Quantitation/Confirmation, Urine • (Forensic) Bath Salts Confirmation, Blood 52365B • (Forensic) Bath Salts Confirmation, 52365SP • Serum/Plasma (Forensic) Bath Salts Confirmation, Urine 52365U • (Forensic) Bath Salts and Stimulants 8756B Designer Drugs - Expanded, • • • Blood Bath Salts and Stimulants 8756SP Designer Drugs - Expanded, • • • Serum/Plasma Bath Salts and Stimulants 8756U Designer Drugs - Expanded, • Urine Cathinones Confirmation 1 52378B • (Qualitative), Blood Cathinones Confirmation 1 52378SP • (Qualitative), Serum/Plasma Cathinones Confirmation 1 52378U • (Qualitative), Urine Cathinones Confirmation 2 52379B • (Qualitative), Blood Cathinones Confirmation 2 52379SP • (Qualitative), Serum/Plasma Cathinones Confirmation 2 52379U • (Qualitative), Urine 52375B DMAA Confirmation, Blood • DMAA Confirmation, 52375SP • Serum/Plasma 52375U DMAA Confirmation, Urine • NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 2 of 76 Effective Date: Monday, August 26, 2013 New Tests and Test Updates Test Test Name New Test Method / Specimen Stability Scope Units Reference Discontinue Code Test Name CPT Code Req. Comments Drug Impaired Driving/DRE 54361B Methcathinone Confirmation, • Blood (Forensic) Drug Impaired Driving/DRE 54361SP Methcathinone Confirmation, • Serum/Plasma (Forensic) Drug Impaired Driving/DRE 54361U Methcathinone Confirmation, • Urine (Forensic) Drug Impaired Driving/DRE 54000B Toxicology Amphetamines • Confirmation, Blood (Forensic) Drug Impaired Driving/DRE Toxicology Amphetamines 54000SP • Confirmation, Serum/Plasma (Forensic) Drug Impaired Driving/DRE 54000U Toxicology Amphetamines • Confirmation, Urine (Forensic) Drug Impaired Driving/DRE 8074B Toxicology Hallucinogens Add- • • On, Blood (Forensic) Drug Impaired Driving/DRE 8074U Toxicology Hallucinogens Add- • • On, Urine (Forensic) Drug Impaired Driving/DRE Toxicology MDMA Confirmation 54323B • (Qualitative), Blood (Forensic) (CSA) Drug Impaired Driving/DRE Toxicology MDMA Confirmation 54326B • (Qualitative), Blood (Forensic) (CSA) Drug Impaired Driving/DRE Toxicology MDMA Confirmation 54323U • (Qualitative), Urine (Forensic) (CSA) Drug Impaired Driving/DRE Toxicology MDMA Confirmation 54326U • (Qualitative), Urine (Forensic) (CSA) Drug Impaired Driving/DRE Toxicology Piperazine Designer 54340B • Drugs Confirmation, Blood (Forensic) Drug Impaired Driving/DRE Toxicology Piperazine Designer 54340SP • Drugs Confirmation, Serum/Plasma (Forensic) NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 3 of 76 Effective Date: Monday, August 26, 2013 New Tests and Test Updates Test Test Name New Test Method / Specimen Stability Scope Units Reference Discontinue Code Test Name CPT Code Req. Comments Drug Impaired Driving/DRE Toxicology Piperazine Designer 54340U • Drugs Confirmation, Urine (Forensic) Drug Impaired Driving/DRE Toxicology Tramadol and 54128B • Metabolite Confirmation, Blood (Forensic) Drug Impaired Driving/DRE Toxicology Tramadol and 54128SP • Metabolite Confirmation, Serum/Plasma (Forensic) Drug Impaired Driving/DRE Toxicology Tramadol and 54128U • Metabolite Confirmation, Urine (Forensic) Hallucinogens Panel 2 52404B • Confirmation, Blood (Forensic) Hallucinogens Panel 2 52404SP Confirmation, Serum/Plasma • (Forensic) Hallucinogens Panel 2 52404U • Confirmation, Urine (Forensic) Hallucinogens Screen - 8755B • • Expanded, Blood Hallucinogens Screen - 8755SP • Expanded, Serum/Plasma Hallucinogens Screen - 8755U • • Expanded, Urine Hallucinogens and Stimulants 52382B Confirmation 1 (Qualitative), • Blood Hallucinogens and Stimulants 52382SP Confirmation 1 (Qualitative), • Serum/Plasma Hallucinogens and Stimulants 52382U Confirmation 1 (Qualitative), • Urine Hallucinogens and Stimulants 52383B Confirmation 2 (Qualitative), • Blood Hallucinogens and Stimulants 52383SP Confirmation 2 (Qualitative), • Serum/Plasma Hallucinogens and Stimulants 52383U Confirmation 2 (Qualitative), • Urine 2541B LSD Screen, Blood • 8334B LSD, Blood (Forensic) • MDMA / Methedrone 52377B • Confirmation (Qualitative), Blood NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 4 of 76 Effective Date: Monday, August 26, 2013 New Tests and Test Updates Test Test Name New Test Method / Specimen Stability Scope Units Reference Discontinue Code Test Name CPT Code Req. Comments MDMA / Methedrone 52412B Confirmation (Qualitative), Blood • (Forensic) MDMA / Methedrone 52377SP Confirmation (Qualitative), • Serum/Plasma MDMA / Methedrone 52412SP Confirmation (Qualitative), • Serum/Plasma (Forensic) MDMA / Methedrone 52377U • Confirmation (Qualitative), Urine MDMA / Methedrone 52412U Confirmation (Qualitative), Urine • (Forensic) Methcathinone (CAT) 53075B • Confirmation, Blood (Forensic) Methcathinone Confirmation 52430B • (Qualitative), Blood (Forensic) Methcathinone Confirmation 52430SP (Qualitative), Serum/Plasma • (Forensic) Methcathinone Confirmation 52430U • (Qualitative), Urine (Forensic) PMA Confirmation (Qualitative), 52432B • Blood (Forensic) PMA Confirmation (Qualitative), 52432SP • Serum/Plasma (Forensic) PMA Confirmation (Qualitative), 52432U • Urine (Forensic) Phenazepam Confirmation 52386B • (Qualitative), Blood Phenazepam Confirmation 52386SP • (Qualitative), Serum/Plasma Phenazepam Confirmation 52386U • (Qualitative), Urine Phenethylamines Confirmation 1 52384B • (Qualitative), Blood Phenethylamines Confirmation 1 52384SP • (Qualitative), Serum/Plasma Phenethylamines Confirmation 1 52384U • (Qualitative), Urine Phenethylamines Confirmation 2, 52385B • Blood Phenethylamines Confirmation 2, 52385SP • Serum/Plasma Phenethylamines Confirmation 2, 52385U • Urine Tramadol and Metabolite 53128B • Confirmation, Blood (Forensic) Tramadol and Metabolite 53128SP Confirmation, Serum/Plasma • (Forensic) NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 5 of 76 Effective Date: Monday, August 26, 2013 New Tests and Test Updates Test Test Name New Test Method / Specimen Stability Scope Units Reference Discontinue Code Test Name CPT Code Req. Comments Tramadol and Metabolite 53128U • Confirmation, Urine (Forensic) NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 6 of 76 Effective Date: Monday, August 26, 2013 New Tests and Test Updates Test Changes 52381SP 7-Hydroxymitragynine, Mitragynine, Phenazepam Confirmation (Qualitative), Serum/Plasma Summary of Changes: Reference Comment was changed. Scope of Analysis: LC-MS/MS (83788): Phenazepam, 7-Hydroxymitragynine, Mitragynine Method (CPT Code) Compound Name Units Reference Comment Phenazepam ng/mL Phenazepam is a benzodiazepine drug. It has CNS depressant properties and likely shares anticonvulsant, muscle relaxant and hypnotic effects with other benzodiazepines, although it has not been thoroughly characterized. It is not legally available in the United States, but is available in Europe. In spite of the fact that it is a CNS depressant it has been identified in some 'Bath Salts' type products. The drug is usually taken orally. 7-Hydroxymitragynine ng/mL 7-Hydroxymitragynine is an active metabolite of mitragynine and a natural alkaloid found in the Kratom plant. It is believed to have stimulant and analgesic properties. No serum or plasma concentration data are available. Mitragynine ng/mL Mitragynine is an alkaloid found in the plant Kratom which originates from Asia. The leaves of plant are consumed for their stimulant and analgesic effects and these effects are attributed to mitragynine. Plant extracts are sold for their medicinal use and may be subject
Recommended publications
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd

    Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd

    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020

    Federal Register/Vol. 85, No. 178/Monday, September 14, 2020

    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
  • Structure-Cytotoxicity Relationship Profile of 13 Synthetic Cathinones In

    Structure-Cytotoxicity Relationship Profile of 13 Synthetic Cathinones In

    Neurotoxicology 75 (2019) 158–173 Contents lists available at ScienceDirect Neurotoxicology journal homepage: www.elsevier.com/locate/neuro Structure-cytotoxicity relationship profile of 13 synthetic cathinones in differentiated human SH-SY5Y neuronal cells T ⁎ Jorge Soaresa, , Vera Marisa Costaa, Helena Gasparb,c, Susana Santosd,e, Maria de Lourdes Bastosa, ⁎ Félix Carvalhoa, João Paulo Capelaa,f, a UCIBIO, REQUIMTE (Rede de Química e Tecnologia), Laboratório de Toxicologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Portugal b BioISI – Instituto de Biossistemas e Ciências Integrativas, Faculdade de Ciências, Universidade de Lisboa, Portugal c MARE - Centro de Ciências do Mar e do Ambiente, Escola Superior de Turismo e Tecnologia do Mar, Instituto Politécnico de Leiria, Portugal d Centro de Química e Bioquímica (CQB), Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Portugal e Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Portugal f FP-ENAS (Unidade de Investigação UFP em Energia, Ambiente e Saúde), CEBIMED (Centro de Estudos em Biomedicina), Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Portugal ARTICLE INFO ABSTRACT Keywords: Synthetic cathinones also known as β-keto amphetamines are a new group of recreational designer drugs. We Synthetic cathinones aimed to evaluate the cytotoxic potential of thirteen cathinones lacking the methylenedioxy ring and establish a Classical amphetamines putative structure-toxicity profile using differentiated SH-SY5Y cells, as well as to compare their toxicity to that Cytotoxicity of amphetamine (AMPH) and methamphetamine (METH). Cytotoxicity assays [mitochondrial 3-(4,5-dimethyl-2- SH-SY5Y cells thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reduction and lysosomal neutral red (NR) uptake] per- Structure-toxicity relationship formed after a 24-h or a 48-h exposure revealed for all tested drugs a concentration-dependent toxicity.
  • Active Constituents Identification Chart (May 2010, Pre-Ban)

    Active Constituents Identification Chart (May 2010, Pre-Ban)

    Head Shop ‘Legal Highs’ Active Constituents Identification Chart (May 2010, pre-ban) •Mephedrone •Mephedrone •Mephedrone •Mephedrone •Methylone •Methylone •Methylone (66.1% as HCl salt, (82.2% as HCl salt, (14.6% as HCl salt, (39.9% as HCl salt, 54.8% as free base) 68.1% as free base ) 12.1% as free base) 33.1% as free base) •Caffeine •Benzocaine •Benzocaine •Methylone •Mephedrone •Flephedrone •Flephedrone •MDPV •Caffeine •MDPV •Lignocaine •Lignocaine •Dimethylamylamine (DMAA) •Caffeine •Caffeine Pack 1 Pack 2 •Flephedrone •MDPV •MDPV •MDPV •Butylone •Butylone •Lignocaine •Lignocaine •Lignocaine •A significant amount of what is believed •MDPV •Caffeine to be an isomer of butylone was also found. •p-Fluorophenylpiperazine •Butylone •m-Trifluoromethylphenylpiperazine •Caffeine (100 %) •Butylone •Dimethylamylamine (DMAA) (pPFP) •Caffeine (mTFMPP) •2-Phenylethylamine (2-PEA) •Caffeine •Caffeine •Hordenine •Caffeine •Methylone •m-Trifluoromethylphenylpiperazine •Mephedrone •2-Aminoindane (2-AI, •MDPV (mTFMPP) 2-indanamine) •1-MthlMethyl-4-bliibenzylpiperazine (MthlMethyl BZP) •CffiCaffeine •Caffeine •m-Trifluoromethylphenylpiperazine •Caffeine (99 %) •Butylone •Butylone (mTFMPP) •MDPV •Mephedrone •p-Fluorophenylpiperazine (pPFP) •Caffeine •Butylone •Mephedrone •2-Phenylethylamine (2-PEA) •Caffeine •Dimethylamylamine (DMAA) •Lignocaine •Dime thy lamy lam ine (DMAA) •Dime thy lamy lam ine (DMAA) •Caffeine These are the active constituents that we have found to date in the above products. It may be expected that Next Generation Compounds (NGC's)
  • AGENDA Friday, September 9, 2016 7:00 A.M

    AGENDA Friday, September 9, 2016 7:00 A.M

    Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted.
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither Jseit005@Fiu.Edu

    Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]

    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)

    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)

    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
  • Treatment, Prevention and Harm Reduction Interventions for Different Forms of ATS Use

    Treatment, Prevention and Harm Reduction Interventions for Different Forms of ATS Use

    Correlation European Harm Reduction C Network Briefing Paper Treatment, prevention and harm reduction interventions for different forms of ATS use Correlation European Harm Reduction C Network 1 Correlation European Harm Reduction C Network Colophon This C-EHRN Briefing Paper was developed by Rafalea Rigoni, Nienke Liebregts and Katrin Schiffer and is based on the results and findings of the ATTUNE study and other relevant literature. More info via: wwww.correlation-net.org https://www.correlation-net.org/attune/ Authors: Rafaela Rigoni Nienke Liebregts Katrin Schiffer Review: Graham Shaw Copyright ©2021 Coyright remains with the publisher. Publisher: De Regenboog Groep/ Correlation-European Harm Reduction Network Stadhouderskade 159 1074BC Amsterdam Netherlands Correlation European Harm Reduction C Network Correlation-European Harm Reduction Network is co-funded by the European Commission This project has been made possible by 2 Correlation European Harm Reduction C Network List of Acronyms 4-FA 4-Fluoroamphetamine (C9H12FN), also known as para-fluoroamphetamine (PFA) 4-MA 4-Methylamphetamine (C10H15N) ADHD Attention Deficit Hyperactivity Disorder ATS Amphetamine Type Stimulants ATTUNE study Understanding Pathways to Stimulant Use: a mixed-methods ex- amination of the individual, social and cultural factors shaping illicit stimulant use across Europe CDU Currently Dependent User CNU Non-dependent Current frequent User EMCDDA The European Monitoring Centre for Drugs and Drug Addiction EU European Union FDU Formerly Dependent User FFU
  • Agenda Florida Hospital Association 307 Park Lake Circle Orlando, FL July 14, 2016 @ 2:00 P.M

    Agenda Florida Hospital Association 307 Park Lake Circle Orlando, FL July 14, 2016 @ 2:00 P.M

    The Florida Board of Nursing Controlled Substances Formulary Committee Agenda Florida Hospital Association 307 Park Lake Circle Orlando, FL July 14, 2016 @ 2:00 p.m. Doreen Cassarino, DNP, ARNP, FNP-BC, BC- ADM, FAANP - Chair Joe Baker, Jr. Executive Director Kathryn L Controlled Substances Formulary Committee Agenda July 14, 2016 @ 2:00 p.m. Committee Members: Doreen Cassarino, DNP, FNP-BC, BC-ADM, FAANP (Chair) Vicky Stone-Gale, DNP, FNP-C, MSN Jim Quinlan, DNP, ARNP Bernardo B. Fernandez, Jr., MD, MBA, FACP Joshua D. Lenchus, DO, RPh, FACP, SFHM Eduardo C. Oliveira, MD, MBA, FCCP Jeffrey Mesaros, PharmD, JD Attorney: Lee Ann Gustafson, Senior Assistant Attorney General Board Staff: Joe Baker, Jr., Executive Director Jessica Hollingsworth, Program Operations Administrator For more information regarding board meetings please visit http://floridasnursing.gov/meeting-information/ Or contact: Florida Board of Nursing 4052 Bald Cypress Way, Bin # C-02 Tallahassee, FL 32399-3252 Direct Line: (850)245-4125/Direct Fax: (850)617-6450 Email: [email protected] Call to Order Roll Call Committee Members: Doreen Cassarino, DNP, FNP-BC, BC-ADM, FAANP (Chair) Vicky Stone-Gale, DNP, FNP-C, MSN Jim Quinlan, DNP, ARNP Bernardo B. Fernandez, Jr., MD, MBA, FACP Joshua D. Lenchus, DO, RPh, FACP, SFHM Eduardo C. Oliveira, MD, MBA, FCCP Jeffrey Mesaros, PharmD, JD Attorney: Lee Ann Gustafson, Senior Assistant Attorney General Board Staff: Joe Baker, Jr., Executive Director Jessica Hollingsworth, Program Operations Administrator I. Review & Approve Minutes from June 29, 2016 Meeting II. Open Discussion A. Recommendations to the Board of Nursing for Rule Promulgation B. Reference Material 1.
  • Alcohol and Drug Abuse Subchapter 9

    Alcohol and Drug Abuse Subchapter 9

    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
  • Long-Term Stability of Synthetic Cathinones in Forensic Toxicology Samples Author(S): Sarah Kerrigan, Ph.D., Lindsay Glicksberg, B.S

    Long-Term Stability of Synthetic Cathinones in Forensic Toxicology Samples Author(S): Sarah Kerrigan, Ph.D., Lindsay Glicksberg, B.S

    NCJRS OFFICE OF JUSTICE PROGRAMS ~ N ATIONAL CRIMINAL JUSTICE REFERENCE SERVICE QJA BJS N/J OJJ[l> OVC SMART ",iiiii~ The author(s) shown below used Federal funding provided by the U.S. Department of Justice to prepare the following resource: Document Title: Long-Term Stability of Synthetic Cathinones in Forensic Toxicology Samples Author(s): Sarah Kerrigan, Ph.D., Lindsay Glicksberg, B.S. Document Number: 251194 Date Received: October 2017 Award Number: 2013-R2-CX-K006 This resource has not been published by the U.S. Department of Justice. This resource is being made publically available through the Office of Justice Programs’ National Criminal Justice Reference Service. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Contents Abstract........................................................................................................................................... 4 Executive Summary ........................................................................................................................ 6 I. Introduction .......................................................................................................................... 10 Statement of the Problem ........................................................................................................ 10 Literature Citations and Review ................................................................................................ 11 Use and